Curanex Pharmaceuticals shares surge 12.96% premarket after completing IPO and exercising over-allotment to raise $17.25 million.

Curanex Pharmaceuticals (NASDAQ:CURX) rose 12.96% in premarket trading following the completion of its initial public offering and the full exercise of its over-allotment option. The company raised $15 million through the IPO priced at $4 per share and secured an additional $2.25 million by exercising the underwriters' over-allotment, totaling $17.25 million in proceeds. These developments, announced in late August and early September 2025, signal strong investor confidence in the biopharmaceutical firm’s capital-raising success and operational capabilities. The news, reported by GlobeNewswire, Seeking Alpha, and QuiverQuant, aligns with the stock’s upward movement, reflecting positive market sentiment toward the company’s recent liquidity and strategic expansion.